-
International Journal of Nanomedicine
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system
Original Research
(6249) Total Article Views
Authors: Min-ting Wang, Yun Jin, Yun-xia Yang, et al
Published Date July 2010 Volume 2010:5 Pages 487 - 497
DOI: http://dx.doi.org/10.2147/IJN.S10393
Min-ting Wang1, Yun Jin1, Yun-xia Yang2, Chun-yan Zhao1, Hong-Yun Yang1, Xue-fan Xu1, Xuan Qin1, Zhao-dan Wang2, Zhi-Rong Zhang1, Yan-lin Jian3, Yuan Huang11Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, 2West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, People’s Republic of China; 3Shenzhen Second People’s Hospital, Shenzhen, People’s Republic of China
Abstract: We aimed to evaluate whether the enhancement of the liver accumulation and anti-inflammatory activity of dexamethasone acetate (DXMA) could be achieved by incorporating it into nanostructured lipid carrier (NLCs). DXMA-NLCs were prepared using a film dispersion-ultrasonication method and characterized in terms of particle size, PDI, zeta potential, differential scanning calorimetry, drug loading capacity, encapsulation efficiency, and in vitro release. The biodistribution and pharmacokinetics of DXMA-NLCs in mice were significantly different from those of the DXMA solution (DXMA-sol). The peak concentration of DXMA-NLCs was obtained half an hour after intravenous administration. More than 55.62% of the total administrated dose was present in the liver. An increase of 2.57 fold in the area under the curve was achieved when compared with that of DXMA-sol. DXMA-NLCs exhibited a significant anti-inflammatory and hepatoprotective effect on carrageenan-induced rats and carbon tetrachloride-induced mice compared with DXMA-sol. However, the effect was not in proportion to the dosage. The intermediate and low dosages presented better effects than DXMA-sol. All results indicate that NLCs, as a novel carrier for DXMA, has potential for the treatment of liver diseases, increasing the cure efficiency and decreasing the side effects on other tissues.
Keywords: dexamethasone acetate, nanostructured lipid carrier, liver targeting
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- ASNM conference 2014
Join us at the American Society for Nanomedicine Conference in Maryland, March 28th - 30th 2014.
- Impact Factors
3.486 Drug Design
3.463 Int J Nanomedicine
2.651 Clin Interv Aging
2.073 Onco Targets Ther
2.000 Neuropsychiatr Dis
1.405 Ther Clin Risk Manag
1.333 Patient Preference - Have an opinion about one of our articles?
We encourage you to write a letter to the editor.
- Interested in being a peer-reviewer?
Click here to register.
- Pre-Submissions
Authors are welcome to send an abstract or draft manuscript to obtain a view from the Editor about the suitability of their paper. Please email here and include which journal you are interested in submitting your manuscript to. Our Editors will do a quick review of your paper and advise if they believe it is appropriate for submission to their journal.
- Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy
- Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer
- Applications of gold nanoparticles in cancer nanotechnology
- Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy
